<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944996</url>
  </required_header>
  <id_info>
    <org_study_id>akparl08</org_study_id>
    <secondary_id>920080174</secondary_id>
    <secondary_id>040-2008</secondary_id>
    <nct_id>NCT00944996</nct_id>
  </id_info>
  <brief_title>Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression</brief_title>
  <official_title>Assessment of PACAP-BDNF Signaling System Involvement in Etiology and Treatment of Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tirat Carmel Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ariel University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Nazareth Hospital, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tirat Carmel Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The neuropeptide Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and its receptors
      PAC1 and VPAC2 are widely expressed in the nervous system. The investigators found that PACAP
      treatment of neuronal cell cultures increases expression of Brain Derived Neurotrophic Factor
      (BDNF) that plays an important role in the etiology of psychiatric disorders and action of
      antidepressants. For the first time, the investigators demonstrated that treatment by
      Paroxetine and Citalopram significantly decreases PAC1 and VPAC2 and upregulates PACAP mRNA
      expression, whereas Imipramine shows an opposite effect. Moreover, PACAP, PAC1 and VPAC2
      expression is highly correlated with BDNF expression. Their in vivo studies show that
      Imipramine reduces BDNF and increases PAC1 mRNA expression in murine hippocampus, suggesting
      that antidepressants may affect neuronal plasticity through PACAP-BDNF interactions. Based on
      their observations in experimental systems, the investigators hypothesize that PACAP
      signaling system may be involved in the etiology of depression and mechanism of
      antidepressant action. The investigators will evaluate this hypothesis by examining serum
      PACAP levels, effect of antidepressants on PACAP levels, and gene polymorphisms of PACAP and
      its receptors in major depressive disorder patients. This study will enhance the
      investigators' understanding of PACAP's role in the etiology of depression and antidepressant
      treatment and will provide a basis to evaluate PACAP pathway as a potential target for
      diagnostics and novel antidepressants drug discovery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurements of PACAP and BDNF serum levels</measure>
    <time_frame>Blood samples will be collected at the study base line, two and three weeks after that and at the study end point (8 weeks after study initiation)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of genetic variants of PACAP and PAC1 coding and regulatory regions</measure>
    <time_frame>Blood samples will be collected at the study base line, two and three weeks after that and at the study end point (8 weeks after study initiation)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>antidepressant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRI; SNRI; TCA</intervention_name>
    <description>Tablets or Pills, 1 or 2 per day, more than 2 month</description>
    <arm_group_label>antidepressant</arm_group_label>
    <other_name>paroxetine, fluoxetine, sertraline, escitalopram, citalopram</other_name>
    <other_name>mirtrazapine, venlafaxine</other_name>
    <other_name>anafranil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women 18-65 age old

          2. Patients with DSM-IV (or/and ICD-10) diagnosis MDD

          3. Volunteers without DSM-IV (or/and ICD-10) diagnosis MDD

          4. For patients with DSM-IV (or/and ICD-10) diagnosis MDD minimum 2 weeks free from
             benzodiazepines, mood stabilizers and neuroleptics.

          5. All patients from MDD group treatment only by SSRI antidepressant medications.

        Exclusion Criteria:

          1. MDD with Co-morbidity

          2. Alcohol and drug use less than 1 month before the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anatoly Kreinin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Pinhasov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Molecular Biology at Ariel University Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leon Raskin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kamal Farhat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Nazareth Hospital-EMMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Farah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Nazareth Hospital-EMMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaudia Rybalksy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Nazareth Hospital-EMMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tirat Carmel Mental Health Center</name>
      <address>
        <city>Tirat Hacarmel</city>
        <zip>30200</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tirat Carmel Mental Health Center</investigator_affiliation>
    <investigator_full_name>Anatoly Dr. Kreinin</investigator_full_name>
    <investigator_title>Director of Psychiatric Department</investigator_title>
  </responsible_party>
  <keyword>PACAP (Pituitary Adenylate Cyclase Activating Polypeptide)</keyword>
  <keyword>Major Depression</keyword>
  <keyword>Receptors</keyword>
  <keyword>Gene polymorphism</keyword>
  <keyword>PACAP signaling system</keyword>
  <keyword>Etiology of major depression</keyword>
  <keyword>Mechanism of antidepressants action</keyword>
  <keyword>PACAP receptors gene polymorphism</keyword>
  <keyword>Pathogenesis of major depression</keyword>
  <keyword>Responsiveness to the antidepressant drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

